No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BOLT Bolt Biotherapeutics
- 0.790
- +0.016+2.00%
Close May 24 16:00 ET
- 0.773
- -0.017-2.20%
Post 17:20 ET
30.12MMarket Cap-475P/E (TTM)
0.810High0.770Low559.28KVolume0.778Open0.775Pre Close442.73KTurnover2.61%Turnover RatioLossP/E (Static)38.13MShares1.86052wk High0.29P/B16.93MFloat Cap0.73452wk Low--Dividend TTM21.43MShs Float43.070Historical High--Div YieldTTM5.17%Amplitude0.734Historical Low0.791Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Earnings Call Summary | Bolt Biotherapeutics(BOLT.US) Q1 2024 Earnings Conference
The following is a summary of the Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript:Financial Performance:Bolt Biotherapeutics did not provide specific financial performance data duri
Bolt Biotherapeutics Inc (BOLT) (Q1 2024) Earnings Call Transcript Highlights: Strategic Shifts ...
Bolt Biotherapeutics Cut to Market Perform From Outperform by Leerink Partners
Bolt Biotherapeutics Cut to Market Perform From Outperform by Leerink Partners
Express News | Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform, Lowers Price Target to $1
NTRB, AERT and SPWR Among Mid-day Movers
Express News | HC Wainwright & Co. Downgrades Bolt Biotherapeutics to Neutral
Comments
$Bolt Biotherapeutics(BOLT.US$ MT Newswires· 2 mins ago
Bolt Biotherapeutics (BOLT) shares were nearly 32% lower in premarket activity Wednesday following the company's announcement late Tuesday that it will stop the development of trastuzumab imbotolimod, BDC-1001, and has trimmed its workforce by about 50%.
The company said the BDC-1001 program is not expected to meet its pre-defined success criteria and it will now focus on developing its other cancer pipeline, which includes a first-in...
Bolt Biotherapeutics (BOLT) shares were nearly 32% lower in premarket activity Wednesday following the company's announcement late Tuesday that it will stop the development of trastuzumab imbotolimod, BDC-1001, and has trimmed its workforce by about 50%.
The company said the BDC-1001 program is not expected to meet its pre-defined success criteria and it will now focus on developing its other cancer pipeline, which includes a first-in...
$Bolt Biotherapeutics(BOLT.US$ Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu® 2 MINUTES AGO, 7:00 AM EST VIA GLOBENEWSWIRE![]()
1
1
$Bolt Biotherapeutics(BOLT.US$ Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 25.86 percent increase over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $2.53 million which beat the analyst consensus estimate of $1.72 million by 46.98 percent. This is a 19.70 percent increase over sales of $2.11 million the same perio...
$Bolt Biotherapeutics(BOLT.US$ Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023![]()
$Bolt Biotherapeutics(BOLT.US$ Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers![]()
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg